Skip to content
Search

Latest Stories

Pharmacists urge Keir Starmer to appoint medicine supply Tsar to address growing shortage crisis

Pharmacists urge Keir Starmer to appoint medicine supply Tsar to address growing shortage crisis

Recent analysis by the NPA revealed that the number of SSPs issued by the Department of Health when medicine shortages are most acute has more than tripled in the past two years

Community pharmacists are calling on the new Labour government led by Keir Starmer to appoint a medicine supply Tsar to address the worsening medicine shortage crisis, as recent polling reveals that around three in ten patients have experienced difficulties obtaining medicines they need.


The National Pharmacy Association (NPA), representing independent community pharmacies, has stressed the need for a 'medicine shortages Tsar' to get a grip on the problem that has blighted both patients and pharmacies in recent years.

A YouGov survey commissioned by the NPA found that in the past year, 28 per cent of people were unable to collect a prescription from their local pharmacy due to medicine shortages.

Among those affected, 6 per cent experienced this 3-4 times, and 5 per cent encountered it five times or more in the last year alone. Of these patients, 32 per cent reported that the shortages had adversely affected their health, with 7 per cent  stating it had a 'great deal' of impact and 25 per cent noting a 'fair deal' of impact.

The NPA emphasised that the proposed Tsar would be responsible for investigating the robustness of the UK's medicine supply chain and enhancing the country's competitiveness in the global medicines market.

Further, the association noted that this role would ideally be filled by an independent expert with technical knowledge of medicine supply, capable of bringing together a wide range of industry organisations to tackle this complex problem.

Recent analysis by the NPA revealed that the number of Serious Shortage Protocols (SSPs), issued by the Department of Health when shortages are most acute, has more than tripled in the past two years. 78 per cent of all SSPs were issued between 2022 and 2024.

SSPs have been issued for a diverse range of medication treating conditions including; cystic fibrosis, angina, menopause symptoms, whooping cough, chest infections, contraception, depression, epilepsy, thyroid problems and anaphylaxis among many others.

Paul Rees, CEO of NPA, said: “These are incredibly worrying statistics which shows the current crisis in medicine supply is having a serious impact on people’s health.

“Although for some, a medicine shortage is frustrating and inconvenient, for others it can be potentially life threatening and have a drastic impact on how a patient can live their life.  We have seen this with the most recent shortages relating to Creon, which can be used to help those living with cystic fibrosis digest food.

“That is why we are urging the new government to appoint a medicine shortages Tsar to use this opportunity to bring together all bodies to tackle this growing and complex crisis once and for all.”

Due to shortages, pharmacies are often forced to spend hours sourcing alternative medications, driving up the cost of drugs.

Some pharmacists have reported to the NPA that ordering short-supply medications, including treatments for common conditions such as hay fever, can cost them 3 to 27 times more than the original price.

The pressure on community pharmacies is further exacerbated by a 40 per cent reduction in their funding, leading to the closure of 10 pharmacies per week so far this year.

“Medicine shortages heap pressure on already stretched community pharmacies, who have to pay inflated prices for medicines in short supply, spend hours trying to find supplies and sometimes face the heartbreaking situation of having to turn patients away,” Paul said.

More For You

Walgreens Boots Alliance acquired by Sycamore in deal

Walgreens Boots Alliancehas entered into “a definitive agreement” to be acquired by Sycamore Partners

Gettyimages

Walgreens Boots Alliance acquired by Sycamore in £18.3 billion deal

Walgreens Boots Alliance(WBA) has entered into “a definitive agreement” to be acquired by Sycamore Partners, a private equity firm specializing in retail, consumer and distribution-related investments.

“The total value of the transaction represents up to $23.7 billion (£18.3 billion),” the company announced late last night (6).

Keep ReadingShow less
Professor Sir Stephen Powis at a press briefing

Professor Sir Stephen Powis, was appointed national medical director of NHS England in 2018

NHS

NHS England’s top doctor to step down following Amanda Pritchard’s resignation

Just a week after NHS England chief executive Amanda Pritchard announced her resignation, the organisation’s national medical director, Professor Sir Stephen Powis, has confirmed he will step down this summer after more than seven years in the role.

In a statement released on Thursday, Professor Powis revealed that he had informed Pritchard of his intention to leave in a letter back in January.

Keep ReadingShow less
PDA calls on GP practices to use funding boost to improve job security for pharmacists

Now, it is time to focus on the community pharmacy contract

gettyimages

PDA urges GP practices to ensure funding boost supports employed pharmacists

The Pharmacists' Defence Association (PDA) has called on GP practicesto ensure that all healthcare professionals they employ, including pharmacists, benefit from the 7.2% funding boost they received under a newly agreed contract.

GP employers are encouraged to improve “job security, pay and conditions” for employees with this increased funding.

Keep ReadingShow less
Fourth Shift: Investment in Innovative Medicines Crucial for NHS 10-Year Plan Success

Medicines should be viewed as an investment rather than a cost

gettyimages

ABPI wants to see a ‘fourth shift’ in NHS 10-Year Health Plan


The Association of the British Pharmaceutical Industry (ABPI) has called on the government to increase investment in innovative medicines and vaccines, describing it as a crucial “fourth shift” necessary to ensure the NHS is fit for the future.

Keep ReadingShow less
Lawrence Tallon named new MHRA chief executive

Lawrence Tallon

Photo credit: Sciana Network

Lawrence Tallon named new MHRA chief executive

Lawrence Tallon has been appointed as the new chief executive officer of the Medicines and Healthcare products Regulatory Agency (MHRA), effective 1 April 2025.

He will succeed Dame June Raine DBE, who is retiring after leading the agency since 2019.

Keep ReadingShow less